Small molecules which reverse Etanercept treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00012105
TitleSmall molecules which reverse Etanercept treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Etanercept treatment in the skin lesion cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1e16ee467bea600fb944e
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis CuratorMicrotaskManic
CREEDS IDdrug:2606
Cell Typeskin lesion
Drug NameEtanercept
DrugBank IDDB00005
Organismhuman
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM300750, GSM300756, GSM300762, GSM300768, GSM300774, GSM300780, GSM300786, GSM300792, GSM300798, GSM300804, GSM300810, GSM300815, GSM300821, GSM300827, GSM300833
Perturbed SamplesGSM300751, GSM300757, GSM300763, GSM300769, GSM300775, GSM300781, GSM300787, GSM300793, GSM300799, GSM300805, GSM300811, GSM300816, GSM300822, GSM300828, GSM300834
Tools used in the analysis
Dataset Accession
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Datasets used in the analysis
Keyword
Tool Name
GSE11903
Gene Expression Omnibus
Effective treatment of psoriasis with etanercept is linked to suppression of IL17 signaling, not immediate response TNF
28
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.